top of page

Hereditary Cancer Syndromes >   BRIP1, BARD1, RAD51C, RAD51D

BRIPOverview.jpg
BARD1Risks2.png
RAD51CRisks3.png
RAD51DRisks4.png
BRIP-associated_syndrome.png
medical_managment-key.png

CANCER

GENETIC CANCER RISK

Female Breast

High Risk

medical_managment-key.png

CANCER

GENETIC CANCER RISK

Ovarian

High Risk

medical_managment-key.png

CANCER

GENETIC CANCER RISK

Ovarian

High Risk

Breast

Elevated Risk

medical_managment-key.png

CANCER TYPE

AGE RANGE

CANCER RISK

RISK FOR GENERAL POPULATION 

Female Breast

To age 80

20%

10.6%

medical_managment-key.png

CANCER TYPE

AGE RANGE

CANCER RISK

RISK FOR GENERAL POPULATION 

Ovarian

To age 80

5.8%

0.9%

medical_managment-key.png

CANCER TYPE

AGE RANGE

CANCER RISK

RISK FOR GENERAL POPULATION 

Ovarian

To age 50

1.0%

0.2%

To age 80

6.7%

0.9%

Female Breast

To age 80

Elevated risk, with a particularly increased risk for Triple Negative Breast Cancer (TNBC).

10.6%

medical_managment-key.png

CANCER TYPE

AGE RANGE

CANCER RISK

RISK FOR GENERAL POPULATION 

Ovarian

To age 50

2.3%

0.2%

To age 80

14.8%

0.9%

Female Breast

To age 80

Elevated risk, with a particularly increased risk for Triple Negative Breast Cancer (TNBC).

10.6%

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

FREQUENCY

Female Breast

Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.

Individualized

NA

Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling

When genetic risk is identified, but not before age 21

Every 6 to 12 months

Mammography with consideration of tomosynthesis and consideration of breast MRI with contrast

Age 40, or modified to a younger age based on the family history of breast cancer

Annually

Consider additional risk-reduction strategies.

Individualized

NA

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

FREQUENCY

Ovarian

Consider bilateral salpingo-oophorectomy (BSO).

45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age

NA

Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.

Individualized

NA

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

FREQUENCY

Ovarian

Consider bilateral salpingo-oophorectomy (BSO).

45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age

NA

Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.

Individualized

NA

Female Breast

Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increased risk for Triple Negative Breast Cancer (TNBC) warrants consideration of individualized breast cancer risk-reduction strategies, such as the modification of standard population screening recommendations by starting screening at younger ages, performing screenings at greater frequency, and utilizing more sensitive technologies such as breast MRI.

Individualized

NA

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

FREQUENCY

Ovarian

Consider bilateral salpingo-oophorectomy (BSO).

45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age

NA

Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.

Individualized

NA

Female Breast

Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increased risk for Triple Negative Breast Cancer (TNBC) warrants consideration of individualized breast cancer risk-reduction strategies, such as the modification of standard population screening recommendations by starting screening at younger ages, performing screenings at greater frequency, and utilizing more sensitive technologies such as breast MRI.

Individualized

NA

BRIP-associated_syndrome.png
bottom of page